AIPAC Principal Investigator:
Hans Wildiers said."Hormone receptor-positive breast tumours represent the majority of metastatic breast cancer patients and any active well-tolerated adjunct to the weekly paclitaxel standard of care regimen, is desirable," he added
I think the webcast will paint a much better picture than the announcement yesterday, perhaps not their best work.
Ann: Immutep reports supportive efficacy data from AIPAC study, page-116
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |